About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Detroit | 16,931 Studies Near You | Clareo Health

Clinical Trials LocationsDetroit

Clinical Trials in Detroit

Discover 16,931 clinical trials near Detroit, Michigan. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 10161-10180 of 16,931 trials

COMPLETED< 1 mile

An Study of Patients With Ph- Chromosome-negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the US

NCT02783651

A retrospective chart review study of Philadelphia chromosome-negative R/R ALL patients in the US.

Relapsed/Refractory Acute Lymphoblastic Leukemia

Amgen212 participantsStarted Jun 2016

Tucson, Arizona, United States • Duarte, California, United States • Los Angeles, California, United States +16 more locations

UNKNOWNPhase 217 miles

A Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia

NCT03542851

This is a randomized, placebo-controlled, double-blind, crossover study of oral BTD-001 in adults with Idiopathic Hypersomnia.

Idiopathic Hypersomnia

Balance Therapeutics80 participantsStarted May 2018

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Orange, California, United States +29 more locations

Find Trials by Condition in Detroit

Breast Cancerin Detroit Lung Cancerin Detroit Prostate Cancerin Detroit Colorectal Cancerin Detroit Melanomain Detroit Leukemiain Detroit Lymphomain Detroit Pancreatic Cancerin Detroit Ovarian Cancerin Detroit Brain Cancerin Detroit Diabetes

Data from ClinicalTrials.govTerms

COMPLETEDPhase 336 miles

Combination Chemotherapy in Treating Patients With Breast Cancer

NCT00003088

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs at different times or combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy consisting of either doxorubicin, cyclophosphamide, or paclitaxel given at different times with that of combination chemotherapy consisting of doxorubicin plus cyclophosphamide followed by paclitaxel in treating women with stage II or stage IIIA breast cancer.

Alliance for Clinical Trials in Oncology2,005 participantsStarted Sep 1997

Scottsdale, Arizona, United States • Peoria, Illinois, United States • Urbana, Illinois, United States +16 more locations

COMPLETEDPhase 444 miles

Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment of Major Depressive Disorder

NCT02466477

Evidence exists supporting the ability of genetic variations to influence patient drug response and side effects. Previous studies utilizing an open-label design have shown significant improvement in major depressive disorder (MDD) patient outcomes following use of the GeneSight Psychotropic (GEN) test. The first objective of this trial is to utilize a double-blinded, randomized clinical trial design to replicate previous findings of improvement in clinical outcomes in MDD subjects whose medication therapy was guided by GEN testing. Another objective is to determine the added benefit of Enhanced-GeneSight (E-GEN) compared to GEN for the pharmacogenomic guidance of treatment selections. Furthermore, this trial intends to develop an evidence-based case for the value of GEN and E-GEN to Canadian healthcare payers.

Depressive Disorder, MajorDepressionDepressive Disorder

Assurex Health Inc.542 participantsStarted Jun 2015

Chatham, Ontario, Canada • Hamilton, Ontario, Canada • Hamilton, Ontario, Canada +11 more locations

COMPLETED51 miles

RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism

NCT02596230

RE-COVERY is a large, multi-national, multi-center observational study based on new data collection. The study will enroll and characterize patients within 30 days of being diagnosed with an acute DVT and/or PE. The study has two main objectives. Objective 1 will characterize the DVT / PE patient population. All patients with a DVT and/or PE will be enrolled for cross-sectional characterization of the VTE patient population. Objective 2 will compare the safety and effectiveness of dabigatran etexilate regimens for treatment of VTE in comparison to VKA regimens. Patients treated with dabigatran etexilate or VKA will be followed up for the occurrence of outcome events for up to one year.

Venous Thromboembolism

Boehringer Ingelheim7,797 participantsStarted Nov 2015

Long Beach, California, United States • Miami, Florida, United States • Miami, Florida, United States +219 more locations

COMPLETEDPhase 390 miles

Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women

NCT01080300

Depomed's Gabapentin Extended Release is an investigational, extended release formulation of Gabapentin that is being studied for the treatment of Hot Flashes/Hot Flushes in postmenopausal women

Depomed600 participantsStarted Aug 2010

Birmingham, Alabama, United States • Mobile, Alabama, United States • Phoenix, Arizona, United States +63 more locations

COMPLETEDPhase 390 miles

Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older

NCT01165229

The purpose of this observer-blind study is to evaluate the efficacy, safety and immunogenicity of GSK Biologicals' candidate Herpes Zoster (HZ) vaccine in adults aged ≥ 70 years. Two studies (Zoster-006 \[NCT01165177\] and Zoster-022 \[NCT01165229\]) will be conducted concurrently to evaluate efficacy of GSK1437173A vaccine. A pooled analysis of data from both studies combined will be conducted contingent on each study achieving its objectives. This protocol posting also deals with the outcome measures related to the pooled analysis.

Herpes ZosterHerpes Zoster Vaccine

GlaxoSmithKline14,819 participantsStarted Aug 2010

Mesa, Arizona, United States • Phoenix, Arizona, United States • Phoenix, Arizona, United States +210 more locations

COMPLETEDPhase 3123 miles

Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9

NCT00489970

The purpose of this study is to evaluate the persistence of antibodies against all the vaccine antigens 1, 3, 5 and 9 years after an initial vaccination with Tdap, and also to assess immunogenicity and safety of another dose of Boostrix, administered in this study. This protocol posting deals with objectives and outcome measures of the extension phase. The objectives and outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00346073).

Acellular PertussisTetanusDiphtheria

GlaxoSmithKline1,954 participantsStarted Jun 2007

Huntsville, Alabama, United States • Chandler, Arizona, United States • Mesa, Arizona, United States +34 more locations

COMPLETEDPhase 3164 miles

Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity

NCT02918279

This trial is conducted globally. The aim of this trial is to investigate the effect of liraglutide for weight management in pubertal adolescent subjects with obesity.

Metabolism and Nutrition DisorderObesity

Novo Nordisk A/S251 participantsStarted Sep 2016

Meridian, Idaho, United States • Baton Rouge, Louisiana, United States • Baltimore, Maryland, United States +30 more locations

COMPLETEDPhase 3188 miles

Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms

NCT03629184

This study will evaluate the safety, pharmacokinetics, and efficacy of baloxavir marboxil compared with oseltamivir in a single influenza episode in otherwise healthy pediatric participants (i.e., 1 to \<12 years of age) with influenza-like symptoms.

Hoffmann-La Roche173 participantsStarted Nov 2018

Birmingham, Alabama, United States • Harrisburg, Arkansas, United States • Jonesboro, Arkansas, United States +34 more locations

COMPLETEDPhase 4234 miles

A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)

NCT01734382

PART1 Participants in Part 1 (Run-in-Phase) of study will receive tocilizumab (TCZ) (RoActemra/Actemra) 12 milligrams per kilogram (mg/kg) or 8 mg/kg intravenously (IV) every 2 weeks (Q2W) for up to 24 weeks. Participants who experience a laboratory abnormality during Part 1 may be eligible to move into Part 2 of the study. PART 2 This open-label Phase IV study will evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenicity of tocilizumab in reduced dose frequency in participants with adequately controlled systemic juvenile idiopathic arthritis who have experienced a laboratory abnormality on twice weekly tocilizumab dosing, that has since resolved. Participants will receive tocilizumab 12 mg/kg or 8 mg/kg intravenously every 3 weeks. After 5 consecutive infusions, participants who experience an event of neutropenia, thrombocytopenia or liver enzyme abnormality will move to every 4 weeks tocilizumab administration. Anticipated time on study treatment is 52 weeks.

Juvenile Idiopathic Arthritis

Hoffmann-La Roche35 participantsStarted Jun 2013

Los Angeles, California, United States • Cincinnati, Ohio, United States • Buenos Aires, Argentina +16 more locations

COMPLETEDPhase 4238 miles

A Study Comparing the Dulaglutide Pen and the Semaglutide Pen

NCT03724981

In this study participants will try out two different types of drug injection pens (dulaglutide and semaglutide) on a practice pad and decide which device they prefer. No study drug will be administered.

Diabetes Mellitus, Type 2

Eli Lilly and Company312 participantsStarted Oct 2018

Fresno, California, United States • Long Beach, California, United States • Palm Harbor, Florida, United States +11 more locations

UNKNOWNPhase 4239 miles

OPTIMIST-A Trial: Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on CPAP

NCT02140580

Trial question: Does administration of exogenous surfactant using a minimally-invasive technique improve outcome in preterm infants 25-28 weeks gestation treated with continuous positive airway pressure (CPAP)? Trial hypothesis: That early surfactant administration via a minimally-invasive technique to preterm infants on CPAP will result in a lesser duration of mechanical respiratory support, and a higher incidence of survival without bronchopulmonary dysplasia. Trial design: Multicentre, randomised, masked, controlled trial in inborn preterm infants 25-28 weeks gestation, aged less than 6 hours, requiring CPAP because of respiratory distress, with an FiO2 of \>=0.3 and CPAP pressure 5-8. Infants randomised to surfactant treatment receive 200 mg/kg of poractant alfa (Curosurf) administered under direct laryngoscopy using a surfactant instillation catheter, followed by reinstitution of CPAP. Controls continue on CPAP. The intervention is masked from the clinical team. Care thereafter is as per usual in both groups, other than the requirement to adhere to intubation criteria. The primary outcome is incidence of death or BPD. Secondary outcomes include incidence of death, major neonatal morbidities (BPD, intraventricular haemorrhage, periventricular leukomalacia, retinopathy of prematurity, necrotising enterocolitis), pneumothorax and patent ductus arteriosus; need for intubation and surfactant therapy; durations of mechanical respiratory support, intubation, CPAP, intubation and CPAP, high flow nasal cannula (HFNC), oxygen therapy, intensive care stay and hospitalisation; hospitalisation cost; applicability and safety of the MIST procedure; and outcome at 2 years. The sample size is 303/group, allowing detection of a 33% difference in the primary outcome with 90% power. The trial commenced at Royal Hobart Hospital December 2011 and Royal Women's Hospital during 2012, and will ultimately be conducted over 5 years in multiple centres internationally.

Bronchopulmonary Dysplasia

Menzies Institute for Medical Research486 participantsStarted Dec 2011

New Haven, Connecticut, United States • Honolulu, Hawaii, United States • Evanston, Illinois, United States +13 more locations

COMPLETEDNA265 miles

Proton Radiotherapy for Recurrent Tumors

NCT01126476

The purpose of this study is to determine the feasibility of using proton radiotherapy for reirradiation of recurrent malignancies.

Abramson Cancer Center at Penn Medicine24 participantsStarted Feb 2010

Warrenville, Illinois, United States • Oklahoma City, Oklahoma, United States • Philadelphia, Pennsylvania, United States

COMPLETEDNA383 miles

The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas

NCT03563313

The objective of the study is to assess efficacy and safety of a closed loop system (t:slim X2 with Control-IQ Technology) in a large randomized controlled trial.

Type 1 Diabetes Mellitus

University of Virginia168 participantsStarted Jun 2018

Santa Barbara, California, United States • Stanford, California, United States • Aurora, Colorado, United States +4 more locations

COMPLETED388 miles

Cancer Risk in Organ Transplant Recipients and End-Stage Renal Disease

NCT00904579

Background: * Solid organ transplantation provides life-saving treatment for end-stage organ disease but is associated with an increased cancer risk because of the need for long-term immunosuppression * End-stage renal disease (ESRD), the most common type of end-stage organ disease leading to transplant, is itself linked to increased risk for some cancers * The role of immunosuppression and other factors causing cancer in this setting are not fully understood. Objectives: * To characterize cancer risk in transplant recipients and identify risk factors. * To characterize risk for transmission of cancer from organ donors to recipients. * To describe cancer risk in ESRD. Eligibility: Patients are not required for this study. Data are gathered from existing databases of ESRD patients, organ transplant patients and cancer registries. Design: * Databases of 1) U.S. transplant recipients, donors and wait list candidates and 2) U.S. ESRD patients will be linked to multiple U.S. cancer registries to identify cancers in transplant recipients and ESRD patients. * The spectrum of cancer risk in transplant recipients and ESRD patients will be evaluated in detail. * The cancer risk in transplant recipients will be examined in relation to whether the donors had cancer. * The proposed cancer risk factors (e.g., underlying medical condition, infection with cancer-causing viruses, immunosuppressive medications) documented in transplant and ESRD files will be studied for association with increased risk of particular types of cancer.

Immunocompromised HostOrgan TransplantationCancer

National Cancer Institute (NCI)19,929,901 participantsStarted Jul 2006

Sacramento, California, United States • Denver, Colorado, United States • Hartford, Connecticut, United States +6 more locations

UNKNOWNNA394 miles

Cerclage for Twins With Short Cervical Length ≤ 15mm

NCT03340688

This is a multicenter randomized study designed to determine if ultrasound indicated cerclage reduces the incidence of spontaneous preterm birth \<34 weeks in asymptomatic women with twin gestations and cervical length ≤15mm, diagnosed by transvaginal ultrasound between 16 to 23 6/7 weeks of gestation.

Twin Pregnancy With Antenatal ProblemPreterm BirthShort Cervix

Thomas Jefferson University200 participantsStarted Jun 2017

Washington D.C., District of Columbia, United States • Philadelphia, Pennsylvania, United States • Austin, Texas, United States +5 more locations

COMPLETEDPhase 1/2491 miles

Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme

NCT01260506

The purpose of this study is to evaluate the safety, tolerability and efficacy of VB-111 in patients with Relapsed Glioblastoma Multiforme.

Glioblastoma Multiforme

Vascular Biogenics Ltd. operating as VBL Therapeutics75 participantsStarted Dec 2010

Boston, Massachusetts, United States • Durham, North Carolina, United States • San Antonio, Texas, United States +1 more locations

COMPLETEDPhase 1/2833 miles

Safety, Pharmacokinetics and Efficacy of KBSA301 in Severe Pneumonia (S. Aureus)

NCT01589185

The objectives of this study are to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical outcome of patients who have severe pneumonia caused by Staphylococcus aureus (S. aureus) after a single intravenous administration of KBSA301 in addition of standard of care antibiotic treatment.

Pneumonia Due to Staphylococcus Aureus

Aridis Pharmaceuticals, Inc.48 participantsStarted May 2012

Jacksonville, Florida, United States • Oklahoma City, Oklahoma, United States • Houston, Texas, United States +15 more locations

TERMINATEDPhase 11963 miles

Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)

NCT02603419

This is a Phase 1b, open-label, multi-center study comprising a lead-in phase and an expansion phase. The lead-in phase is a multiple-dose, randomized, parallel-arm, pharmacokinetic and pharmacodynamic study of avelumab as a single agent in adult patients with cHL. Patients enrolled in the lead-in phase of this study are required to have relapsed following a prior autologous or allogeneic HSCT, or to be ineligible for HSCT. Based on the preliminary TO, safety, and efficacy results from the lead-in phase, the expansion phase will evaluate the anti-tumor activity and safety of single-agent avelumab utilizing an intra-patient dose escalation paradigm based on two of the dosing regimens studied in the lead-in phase in 40 cHL patients in whom an allogeneic HSCT has failed.

Hodgkins Lymphoma

Pfizer34 participantsStarted Mar 2016

Duarte, California, United States • Bologna, BO, Italy • Rozzano, Milano, Italy +10 more locations

PreviousPage 509 of 847Next

in Detroit

Heart Diseasein Detroit